The DPS® system's value proposition to health and medical companies is highly tangible and quantifiable. It can help extend patients' lives and drive greater patient compliance, thus improving quality of life for patients requiring injectable drugs while promoting greater revenue growth for the companies that produce them.
Milestone is currently seeking to establish strategic collaborations with companies interested in exploring opportunities to develop new disruptive drug delivery technologies that will enable them to raise the barriers to market entry and differentiate their drug products from those delivered by conventional means.
Milestone anticipates that any application for a device developed utilizing the DPS system will require 510(k) approval from the FDA, which should reduce development cost and time to market.
To explore partnering opportunities, please contact us.
Copyright 2013 Milestone Medical Inc. All Rights Reserved.